Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib

. 2025 Mar ; 104 (3) : 2001-2004. [epub] 20250228

Jazyk angličtina Země Německo Médium print-electronic

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid40016401
Odkazy

PubMed 40016401
PubMed Central PMC12031779
DOI 10.1007/s00277-025-06228-x
PII: 10.1007/s00277-025-06228-x
Knihovny.cz E-zdroje

Chronic myeloid leukemia (CML) treatment has been revolutionized over last 20 years because of tyrosine kinase inhibitors (TKIs) and patients with CML now have life expectancy of general population. Chronic TKI treatment may cause adverse effects (AEs) that vary in frequency and severity. Nilotinib shows common AEs with metabolic changes and skin AEs. Here, we present a case report of patient who experienced full psoriasis regression while treated with nilotinib. Dose reductions and an attempt to stop nilotinib treatment resulted in prompt psoriasis reappearance. This is the first documented case of positive effect of nilotinib on psoriasis.

Zobrazit více v PubMed

Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016. 128(1):17–23. PubMed

Berger MG, Pereira B, Rousselot P et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019. 187(3):337–346. PubMed

Caldemeyer L, Dugan M, Edwards J, Akard L. Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Curr Hematol Malig Rep. 2016. 11(2):71 − 9. PubMed

Steegmann JL, Cervantes F, le Coutre P et al. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012. 53(12):2351-61. PubMed

Jabbour E, Sasaki K, Haddad FG et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am. J. Hematol. 2022. 97(11):1413–1814. PubMed PMC

Nagai T, Karakawa M, Komine M et al. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment. Eur J Haematol. 2013. 91(3):270–272. PubMed

Day E, Waters B, Speigel K et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol. 2008. 599(1–3):44–53. PubMed

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...